MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • Retinal Degeneration
    • Publications
  • News & Media
  • Contact Us
MENUMENU
  • About Us
    • Statement From CEO
    • Our Leadership
    • Partnerships
  • Programs
    • Cancer Immunotherapy
    • Retinal Degeneration
    • Publications
  • News & Media
  • Contact Us
  •  
  • August 2018

AIVITA Biomedical Appoints Chief Financial Officer and Vice President of Business Development

AIVITA Biomedical Announces Initiation of First Clinical Site for ROOT OF CANCER Glioblastoma Trial

AIVITA Biomedical to Speak and Exhibit Skincare Products at August Aesthetics Conferences

AIVITA Biomedical is an immuno-oncology company designing personalized vaccines that target the seed of all cancers: tumor-initiating cells. We leverage our unique expertise in stem cell growth and directed, high-purity differentiation to develop safe, efficient and economical manufacturing processes for therapeutic development in cancer and other fields.

Recent News

  • AIVITA Biomedical CEO Hans Keirstead Named to “20 in 2020” by Consulate General of Canada for Contributions to COVID-19 Research
  • AIVITA Biomedical Publishes Study Comparing Immune Responses and Associated Survivals Induced by Dendritic and Tumor Cell Vaccines
  • AIVITA Biomedical Provides Update of Ongoing Phase 2 Glioblastoma Trial from Year-End Survival Analysis
  • AIVITA Biomedical Raises $12.5 Million in Series B-2 Financing Round and Announces New Board of Directors Appointee
  • AIVITA Biomedical to Present at 2020 BIO CEO & Investor Conference

Site Navigation

  • About Us
  • Programs
  • News & Media
  • Contact Us
Copyright © 2020 | AIVITA Biomedical, Inc.